KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 101–150 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12V6
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	—	accepted	EID2232 In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID3824 One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12V, was wildtype for NRAS… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID6323 In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC	civic
Regorafenib Anhydrous	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID3924 In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12V mutation demonstrated resistance to regorafenib treatment (IC50: 241.90 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC	civic
Gefitinib	Malignant Lung Neoplasm	Predictive	C	Supports Resistance	2	accepted	EID2268 In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC	civic
Crizotinib	Malignant NeoplasmALIAS	Predictive	C	Does Not Support Resistance	2	accepted	EID1715 Case report of a 59-year-old white female patient (60 pack-years) with a CUP-syndrome. Molecular profiling identified both MET amplification (16 copies) and a KRAS G12V mutation. The patient was treat… (full text at CIViC) PMID 25232318 · Palma et al., 2014 · Open in CIViC	civic
KRAS G12D7
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	—	accepted	EID2236 In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID6316 In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS, PIK3CA, and PTEN … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC	civic
Regorafenib Anhydrous
KRAS G12C5
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2253 In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC	civic
Regorafenib Anhydrous	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID3973 In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12C mutation demonstrated resistance to regorafenib treatment (IC50: 386.22 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC	civic
Panitumumab + SotorasibCombination
KRAS G12R2
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	—	accepted	EID2264 In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC	civic
Regorafenib Anhydrous	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	1	accepted	EID3991 In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12R mutation demonstrated resistance to regorafenib treatment (IC50: 181.77 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC	civic
KRAS G12S3
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	—	accepted	EID2269 In a retrospective study of 427 metastatic colorectal patients, KRAS mutations were observed in 43% of the tumor samples. Patients with mutations in codon 12 or 13 of KRAS were associated with reduced… (full text at CIViC) PMID 18316791 · Amado et al., 2008 · Open in CIViC	civic
Regorafenib Anhydrous	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID4012 In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G12S mutation demonstrated resistance to regorafenib treatment (IC50: 264.23 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC	civic
Gefitinib	Malignant Lung Neoplasm
KRAS G13D2
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID6322 In this study, a large cohort of metastatic colorectal cancer patients were treated with anti-epidermal growth factor receptor monoclonal antibodies (cetuximab or panitumumab). KRAS G13D was the only … (full text at CIViC) PMID 19223544 · Sartore-Bianchi et al., 2009 · Open in CIViC	civic
Regorafenib Anhydrous	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	1	accepted	EID3889 In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS G13D mutation demonstrated resistance to regorafenib treatment (IC50: 172.23 nM vs. 114.28 nM, P<0.01) compared to SW4… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC	civic
KRAS Mutation + MET AmplificationMET KRAS1
Cetuximab/Irinotecan Regimen + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID1971 7 patients with acquired resistance to EGFR inhibitors were analyzed in this study. Of these, 4 did not develop KRAS mutations. Post- and Pre-Treatment tissued was available of three patients and MET … (full text at CIViC) PMID 23729478 · Bardelli et al., 2013 · Open in CIViC	civic
KRAS Mutation9
Refametinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID1001 Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD. PMID 23434733 · Weekes et al., 2013 · Open in CIViC	civic
Selumetinib + TeprotumumabCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID1004 Preclinial data from KRAS mutant colorectal cancer cell lines show syngergistic effect on cell viability and apoptosis in vitro and in vivo when MEK and IGF-IR are inhibited concomitantly. In other ce… (full text at CIViC) PMID 21985784 · Ebi et al., 2011 · Open in CIViC	civic
Afatinib + Trametinib
KRAS Exon 2 Mutation3
Regorafenib Anhydrous	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	1	accepted	EID87 KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment. KRAS exon 2 variants… (full text at CIViC) PMID 24559322 · Sartore-Bianchi et al., 2014 · Open in CIViC	civic
Vemurafenib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID8367 This preclinical study examined vemurafenib efficacy on various colorectal cancer cell lines and in vivo via mouse xenograft experiments. Three cell lines harbored KRAS exon 2 mutations and wt BRAF: H… (full text at CIViC) PMID 22180495 · Yang et al., 2012 · Open in CIViC	civic
Erlotinib + Gemcitabine
KRAS G12A6
Regorafenib Anhydrous	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	2	accepted	EID3710 In an in vitro study, a human colon adenocarcinoma SW48 cell line virally transduced to express KRAS G12A demonstrated resistance to regorafenib treatment (IC50: 330.13 nM vs. 114.28 nM, P<0.01, repor… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC	civic
Gefitinib	Malignant Lung Neoplasm	Predictive	B	Supports Resistance	2	accepted	EID2008 In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC	civic
Melphalan	Multiple Myeloma	Predictive	B
KRAS Wildtype1
Regorafenib Anhydrous	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Does Not Support Resistance	2	accepted	EID8840 In an in vitro study, a human colon adenocarcinoma SW48 cell line expressing KRAS wildtype did not demonstrate resistance to regorafenib treatment (IC50: 114.28 nM) compared to SW48 cells expressing v… (full text at CIViC) PMID 26161928 · Camaj et al., 2015 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Mutation + NRAS MutationHRAS BRAF NF1 KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11681 In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Inactivating Mutation + NRAS MutationHRAS NF1 BRAF KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11696 In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E + KRAS G12DBRAF KRAS1
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	2	accepted	EID3957 In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
KRAS Amplification1
Vemurafenib	Melanoma	Predictive	D	Supports Resistance	2	accepted	EID6317 In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF sensitizing mutation) found that cells induced to stably over-express wildtype … (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic
BRAF V600E + KRAS MutationBRAF KRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6264 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Abemaciclib	CA Health Canada	—	Marketed in Canada as VERZENIO (DIN 02487136) under ATC L01EF03 ABEMACICLIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 3, 2019	health-canada-dpd
Abemaciclib	CA Health Canada	—	Marketed in Canada as VERZENIO (DIN 02487098) under ATC L01EF03 ABEMACICLIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 3, 2019	health-canada-dpd
Abemaciclib	CA Health Canada	—	Marketed in Canada as VERZENIO (DIN 02487101) under ATC L01EF03 ABEMACICLIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,651)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 795 recruiting · 365 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 901–950 of 1,651 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04434040	Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)	recruiting	Phase 2	40	Dana-Farber Cancer InstituteOTHER	1	May 4, 2026	clinicaltrials
NCT05456256	A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma(HARMONIC)	recruiting	Phase 2	90	Lantern Pharma Inc.INDUSTRY	3	May 4, 2026	clinicaltrials
NCT05491811	Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation(EAGLE)	active not recruiting	Phase 2	47	Sun Yat-sen UniversityOTHER	1	May 4, 2026	clinicaltrials
NCT06015659	ZN-c3 + Gemcitabine in Pancreatic Cancer	active not recruiting	Phase 2	12	Brandon Huffman, MDOTHER	1	May 4, 2026	clinicaltrials
NCT07563738	A 2-part Phase 1/2 Open-label Trial on ODM-212(TEADCO)	recruiting	Phase 1 / Phase 2	229	Orion Corporation, Orion PharmaINDUSTRY	1	May 4, 2026	clinicaltrials
NCT05195632	Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer(OCEANII)	active not recruiting	Phase 2	63	Pierre Fabre MedicamentINDUSTRY	2	May 1, 2026	clinicaltrials
NCT07478302	A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma	recruiting	Phase 1	36	Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY	1	May 1, 2026	clinicaltrials
NCT07560488	Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma	recruiting	Phase 2	43	Tianjin Medical University Cancer Institute and HospitalOTHER	1	May 1, 2026	clinicaltrials
NCT07561983	Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC(BEACON-Lung)	not yet recruiting	Phase 2	39	Sichuan Cancer Hospital and Research InstituteOTHER	1	May 1, 2026	clinicaltrials
NCT00433420	Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer	active not recruiting	Phase 3	2,000	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, ItalyOTHER	0	Apr 30, 2026	clinicaltrials
NCT03838159	NADIM II: Neo-Adjuvant Immunotherapy(NADIMII)	active not recruiting	Phase 2	90	Fundación GECPOTHER	1	Apr 30, 2026	clinicaltrials
NCT05358548	ATATcH Alternating Treatment Plans for Advanced Cancer	recruiting	Phase 2	150	Rutgers, The State University of New JerseyOTHER	1	Apr 30, 2026	clinicaltrials
NCT05398094	Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy(MERIT-lung)	recruiting	Phase 2	19	Fundación GECPOTHER	1	Apr 30, 2026	clinicaltrials
NCT05608252	VS-6766+Abema+Fulv in Met HR+/HER- BC	recruiting	Phase 1 / Phase 2	63	Adrienne G. WaksOTHER	1	Apr 30, 2026	clinicaltrials
NCT07309952	Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC(SACTION 2501)	recruiting	Phase 2	28	Yang HongOTHER	1	Apr 30, 2026	clinicaltrials
NCT02495896	Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors	active not recruiting	Phase 1	61	University of Southern CaliforniaOTHER	1	Apr 29, 2026	clinicaltrials
NCT03122717	Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer	active not recruiting	Phase 1 / Phase 2	48	Dana-Farber Cancer InstituteOTHER	1	Apr 29, 2026	clinicaltrials
NCT03310879	Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	recruiting	Phase 2	38	Dana-Farber Cancer InstituteOTHER	1	Apr 29, 2026	clinicaltrials
NCT06300424	Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC(NEOVADE)	active not recruiting	Phase 2	32	Guangdong Provincial People's HospitalOTHER	1	Apr 29, 2026	clinicaltrials
NCT03789110	NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer	active not recruiting	Phase 2	30	Dana-Farber Cancer InstituteOTHER	1	Apr 28, 2026	clinicaltrials
NCT05645380	Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC(NeoTRACT)	active not recruiting	Phase 2	139	University of Kansas Medical CenterOTHER	1	Apr 28, 2026	clinicaltrials
NCT07543783	Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial	not yet recruiting	Phase 2	38	Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER	0	Apr 28, 2026	clinicaltrials
NCT05440708	A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma	recruiting	Phase 1 / Phase 2	193	Tvardi Therapeutics, IncorporatedINDUSTRY	1	Apr 27, 2026	clinicaltrials
NCT05522660	Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer(USZ-STRIKE)	recruiting	Phase 3	180	ETOP IBCSG Partners FoundationNETWORK	5	Apr 27, 2026	clinicaltrials
NCT03155997	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer(monarchE)	active not recruiting	Phase 3	5,637	Eli Lilly and CompanyINDUSTRY	38	Apr 24, 2026	clinicaltrials
NCT06679829	A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant	recruiting	Phase 2	215	Memorial Sloan Kettering Cancer CenterOTHER	1	Apr 24, 2026	clinicaltrials
NCT06841055	Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment	recruiting	Phase 2	60	BioNTech SEINDUSTRY	6	Apr 24, 2026	clinicaltrials
NCT07542262	Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers(NIVO402025)	enrolling by invitation	Phase 2	128	Blokhin's Russian Cancer Research CenterOTHER	1	Apr 24, 2026	clinicaltrials
NCT06483555	Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA)	recruiting	Phase 1 / Phase 2	104	UNC Lineberger Comprehensive Cancer CenterOTHER	1	Apr 23, 2026	clinicaltrials
NCT05687266	Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations(AVANZAR)	active not recruiting	Phase 3	1,350	AstraZenecaINDUSTRY	23	Apr 22, 2026	clinicaltrials
NCT07020221	A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors	recruiting	Phase 1 / Phase 2	295	Verastem, Inc.INDUSTRY	2	Apr 22, 2026	clinicaltrials
NCT07543744	A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI	recruiting	Phase 1	180	R-PharmINDUSTRY	1	Apr 22, 2026	clinicaltrials
NCT03389477	Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma	active not recruiting	Phase 2	26	Washington University School of MedicineOTHER	1	Apr 21, 2026	clinicaltrials
NCT03872661	Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC(NIBCUN)	recruiting	Phase 2	36	Sun Yat-sen UniversityOTHER	1	Apr 21, 2026	clinicaltrials
NCT06563999	Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.(NUMER)	recruiting	Phase 2	120	Sun Yat-sen UniversityOTHER	1	Apr 21, 2026	clinicaltrials
NCT07147101	Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment(HCC-IM-1)	recruiting	—	150	Fudan UniversityOTHER	1	Apr 21, 2026	clinicaltrials
NCT07378306	FMD and Neoadjuvant Chemo-immunotherapy in TNBC(FACT-TN)	recruiting	Phase 2	80	Sun Yat-sen UniversityOTHER	1	Apr 21, 2026	clinicaltrials
NCT06280495	Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients	recruiting	Phase 2 / Phase 3	156	Sun Yat-sen UniversityOTHER	1	Apr 20, 2026	clinicaltrials
NCT06828354	A Study of SHR-A1811 in Subjects With Ovarian Cancer	recruiting	Phase 3	300	Jiangsu HengRui Medicine Co., Ltd.INDUSTRY	1	Apr 20, 2026	clinicaltrials
NCT07340164	Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy(TROY)	recruiting	Phase 2	116	Yonsei UniversityOTHER	1	Apr 20, 2026	clinicaltrials
NCT03971409	Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer(InCITe)	active not recruiting	Phase 2	145	Laura Huppert, MD, BAOTHER	1	Apr 17, 2026	clinicaltrials
NCT05633602	Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study	active not recruiting	Phase 3	838	SWOG Cancer Research NetworkNETWORK	1	Apr 17, 2026	clinicaltrials
NCT06382129	A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)	active not recruiting	Phase 3	698	Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY	1	Apr 17, 2026	clinicaltrials
NCT06544655	A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors	active not recruiting	Phase 1	213	Bristol-Myers SquibbINDUSTRY	3	Apr 17, 2026	clinicaltrials
NCT07523763	Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal Cancer(NIVO1002024)	active not recruiting	Phase 2	30	Blokhin's Russian Cancer Research CenterOTHER	1	Apr 17, 2026	clinicaltrials
NCT07527806	Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging	not yet recruiting	Phase 2	156	Peking University Cancer Hospital & InstituteOTHER	0	Apr 17, 2026	clinicaltrials
NCT00479128	Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors	active not recruiting	Phase 1	80	M.D. Anderson Cancer CenterOTHER	1	Apr 16, 2026	clinicaltrials
NCT01187199	Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	active not recruiting	Phase 1	278	M.D. Anderson Cancer CenterOTHER	1	Apr 16, 2026	clinicaltrials
NCT04940286	Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer	active not recruiting	Phase 2	13	M.D. Anderson Cancer CenterOTHER	1	Apr 16, 2026	clinicaltrials
NCT05026983	Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases	recruiting	Phase 2	35	M.D. Anderson Cancer CenterOTHER	1	Apr 16, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,651)

Linked publications (113)